Litigation Details for Tris Pharma Inc. v. Actavis Laboratories FL Inc. (D. Del. 2014)

Tris Pharma Inc. v. Actavis Laboratories FL Inc. (D. Del. 2014)

Docket		Date Filed	2014-10-15
Court	District Court, D. Delaware	Date Terminated	2020-12-03
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	ANDRX CORPORATION
Patents	6,419,960; 7,691,880; 8,062,667; 8,287,903; 8,465,765; 8,563,033; 8,778,390; 8,956,649; 9,040,083
Attorneys	Jennifer Koh
Firms	Barnes and Thornburg LLP
Link to Docket	External link to docket

Details for Tris Pharma Inc. v. Actavis Laboratories FL Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-15	1		“Notification of Certification for U.S. Patent Nos. 8,062,667; 8,287,903; 8,465,765; 8,563,033 and 8,778,390…States Patent No. 8,465,765 (“the ’765 patent”), United States Patent No. 8,563,033 (“the ’033 patent”), …Actavis has infringed the ’765 patent, the ’033 patent, and the ’390 patent by submitting ANDA 206049 to… to infringement of the ’765 patent, the ’033 patent, and the ’390 patent; -15_ Case 1:14-ov-01309-UNA…after the expiration of the ’765 patent, the ’033 patent, the ’390 patent, or any later expiration of exclusivity	External link to document
2017-09-05	161		1 and Cmax-2)." 153. U.S. Patent No. 6,419,960 ("Krishnamurthy") issued on July…667 Patent, the '903 patent, the '765 patent, the '033 patent, the '390 patent, the…the '649 patent, and the '083 patent (collectively, "the patents-in-suit") are listed… '667 patent is cited on the face of each of the patents-in-suit. The '667 patent expires on…the patents-in-suit. The '667 patent identifies Tris as the assignee of the '667 patent, who	External link to document
2020-11-29	201	Opinion - Memorandum Opinion	in five patents: U.S. Patent Nos. 8,465,765 (the #765 patent), 8,563,033 (the #033 patent), 8,778,390…,390 (the #390 patent), 8,956,649 (the #649 patent), and 9,040,083 (the #083 patent}. Tris Pharma, Inc… #033 patent, claims 6 and 20 of the #765 patent, and claims 15, 16, and 20 of the #390 patent. The Federal… the #033 patent, claim 6 of the #765 patent, and claims 15, 16, and 20 of the #390 patent. Actavis… the #033 patent, claim 6 of the #765 patent, and claims 15, 16, and 20 of the #390 patent are invalid	External link to document
2020-12-03	205	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,465,765 B2; 8,563,033 B1; 8,778,390…2014 4 December 2020 1:14-cv-01309 830 Patent None District Court, D. Delaware	External link to document
2014-10-15	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,465,765 B2; 8,563,033 B1; 8,778,390…2014 4 December 2020 1:14-cv-01309 830 Patent None District Court, D. Delaware	External link to document
2015-12-17	92		Actavis”) alleging infringement of U.S. Patent Nos. 8,465,765, 8,563,033 and 8,778,390 in connection with…Actavis alleging infringement of U.S. Patent No. 8,956,649 (“the ’649 patent”) in Case 1:14-cv-01309-GMS Document…Actavis alleging infringement of U.S. Patent No. 9,040,083 (“the ’083 patent”) in connection with the filing… XR® product prior to the expiration of those patents; WHEREAS on May 15, 2015, Tris filed a …Quillivant XR® product prior to the expiration of that patent; WHEREAS on July 13, 2015, the parties	External link to document
2015-12-20	93		quot;) alleging . infringement of U.S. Patent Nos. 8,465,765, 8,563,033 and 8,778,390 in connection with…alleging infringement of U.S. Patent No. 8,956,649 (''the '649 patent") in Case 1:14-cv-…alleging infringement of U.S. Patent No. 9,040,083 ("the '083 patent") in connection with… XR® product prior to the expiration of those patents; WHEREAS on May 15, 2015, Tris filed a…Quillivant XR® product prior to the expiration of that patent; WHEREAS on July 13, 2015, the parties	External link to document